← Home / Elicio Therapeutics, Inc. (ELTX)
Stock Analysis
Elicio Therapeutics, Inc. (ELTX)
ELTX
ELTX · Market data
3.18 +0.95%
Track ELTX in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when ELTX price is:
52W Range Position
3%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-09 19:34 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Insufficient / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
5.08
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
JUL
2
●
Material Agreement
HIGH
ELTX material agreement
Each share of Common Stock was sold at an offering price of $3.43.
8-K Filing • SEC EDGAR
JUL
2
↗
Equity Offering / Capital Raise
HIGH
ELTX equity financing update
Each share of Common Stock was sold at an offering price of $3.43.
8-K Filing • SEC EDGAR
MAY
11
●
Financial Results
HIGH
Elicio’s AMP platform, originally developed at the Massachusetts Institute of Technology, has broad potential in the cancer space to advance a number of development initiatives through internal activities, in-licensing a
eltx1q26pr Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates • In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), the event-driven primary disease-free survival (“DFS”) analysis is anticipated mid-yea...
8-K Filing • SEC EDGAR
What's Driving ELTX?
📈 Technical recovery is improving
Momentum is Neutral. Watch 5.08 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
41.0
Price Chart
ELTX — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-08-07
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$59.3M
Company size
EV
$54.6M
Debt-adjusted value
P/E
-1.5
Not meaningful
P/S
25.8
Very high
P/B
-41.2
Not meaningful
EV/Sales
23.7
Very high
EV/EBIT
-1.5
Not meaningful
P/FCF
-1.5
Not meaningful
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial conditions require selective monitoring.
↗
Revenue Growth
Insufficient
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
0.00
≈ Insufficient
📈 Net Income
-11.82M
↘ Negative
🧮 EPS (Basic)
-0.65
↘ Negative
Elicio Therapeutics, Inc.
Related Opportunities